Xbrane Sets Cash Target Ahead Of Lucentis Ambitions In 2022
Swedish Firm Names New Strategic Targets
Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.
Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.